CTOs on the Move


 
Securing our nation’s pharmaceuticals through U.S. Manufacturing.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Dave Levin
Chief Medical and Information Officer Profile

Similar Companies

Jubilant Pharma

Follow us for career advice, news & jobs. Find your Formula for Success at Jubilant Pharma! Subsidiaries: HollisterStier, Cadista, Radiopharma, and JGL.

Ferndale Laboratories

Perhaps the most important decision in determining the destiny of Ferndale Laboratories, Inc. was made in the Fall of 1975. At that time, Ferndale Laboratories, Inc. embarked on a mission to grow from a local pharmaceutical manufacturer to a company with

Summa Health

Summa Health is one of the largest integrated delivery systems in Ohio. Encompassing a network of hospitals, community health centers, a health plan, a physician-hospital organization, a multi-specialty physician organization, research and multiple foundations, Summa is nationally renowned for excellence in patient care and for exceptional approaches to healthcare delivery. Summa also is a founding partner of the BioInnovation Institute in Akron. For more information, visit www.summahealth.org. Summa Health is an Affirmative Action employer that promotes Equal Employment Opportunity and Diversity for all individuals. Women, veterans, members of minority groups, and individuals with disabilities are encouraged to apply.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.